| RL |
Report |
Revenue growth (FX-neutral) |
BEAT |
pred ~10% vs. cons 8% |
MEDIUM |
| RL |
Report |
Adjusted EPS |
BEAT |
pred ~$4.55 vs. cons $4.29 |
MEDIUM |
| RL |
Report |
Adjusted operating margin |
BEAT |
pred ~18.7% vs. cons 18.3% |
LOW |
| RL |
Guide |
FY27 revenue growth (cc, full year) |
BETTER |
guide raised to ~6-7% vs. cons ~5% (FY27) |
MEDIUM |
| RL |
Guide |
FY27 operating margin expansion (full year) |
UNCHANGED |
guide +40-60 bps vs. cons ~+50 bps (FY27) |
MEDIUM |
| RL |
Guide |
AUR growth (Q1, high-single-digit) |
BETTER |
pred ~9% vs. cons ~8% (FQ1 FY27) |
LOW |
| RL |
Guide |
Tariff/IEEPA refund optionality (2H commentary) |
UNKNOWN |
guide excludes refunds (upside ~unquantified) vs. cons $0 assumed (2H FY27) |
LOW |
| RL |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| RL |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
Classic 'clean beat, priced-for-perfection' RL setup (year-ago FQ1 fell ~6.5% on a beat-and-raise). Even with an FX-neutral revenue/EPS beat and a modest FY raise, the out-period math is unfavorable: FY27 margin expansion is front-half weighted with a tariff step-up assumed in 2H and stiffening Asia/China (+40%) and AUR (+14%) compares, so 2H estimates get trimmed even after a Q1 beat. That, plus a rich valuation only ~8% off highs, pulls the initial negative reaction further over the week as sell-side normalizes out-quarter numbers. |
MEDIUM |